Bioorganic and medicinal chemistry (2020)
Update date:2022-07-29
Topics:
Ambler, Catherine M.
Arnold, Eric
Banker, Mary Ellen
Clark, James D.
Dowty, Martin E.
Efremov, Ivan V.
Fensome, Andrew
Flick, Andrew
Gerstenberger, Brian S.
Gifford, Roger S.
Gopalsamy, Ariamala
Hegen, Martin
Jussif, Jason
Limburg, David C.
Lin, Tsung H.
Pierce, Betsy S.
Sharma, Raman
Trujillo, John I.
Vajdos, Felix F.
Vincent, Fabien
Wan, Zhao-Kui
Xing, Li
Yang, Xiaojing
Yang, Xin
Herein, we disclose a new series of TYK2/ JAK1 inhibitors based upon a 3.1.0 azabicyclic substituted pyrimidine scaffold. We illustrate the use of structure-based drug design for the initial design and subsequent optimization of this series of compounds. One advanced example 19 met program objectives for potency, selectivity and ADME, and demonstrated oral activity in the adjuvant-induced arthritis rat model.
View MoreShanghai He Yang International Trading Co., Ltd.
Contact:+86-21-52043598
Address:Room 816, Blag.5, No.58 Huachi Road
Contact:18698110882
Address:1303 No2 building,LuoMa Garden,YongAn Road,Hexi District,Tianjin city
Chengdu Green Young Biopharmaceutical INC
Contact:+86-28-85337952
Address:1-B-26,Tianhe Industry Park, No.1480 of Tianfu Road,Chengdu,P.R.China,610000
Contact:86-21-50966856
Address:Building 5,300 Chuanzhan Road,Pudong New District,Shanghai
Contact:13813902930 025-52714267
Address:20 Fengji Road, Yuhua Economic Development Zone, Nanjing, Jiangsu, P. R. China
Doi:10.1016/S0040-4020(01)81726-9
(1988)Doi:10.1016/S0040-4039(00)96613-9
(1987)Doi:10.1016/j.bmcl.2013.09.041
(2013)Doi:10.1016/S0040-4039(00)96656-5
(1987)Doi:10.1021/bi100538b
(2010)Doi:10.1002/chem.201400315
(2014)